STERIS (STE)

NYSE: STE · Real-Time Price · USD

222.83

-1.91 (-0.85%)

At close: May 01, 2025, 12:08 PM

-0.85% (1D)

Bid	222.55
Market Cap	21.89B
Revenue (ttm)	5.4B
Net Income (ttm)	467.59M
EPS (ttm)	6.23
PE Ratio (ttm)	35.77
Forward PE	22.42
Analyst	Buy

Ask	222.97
Volume	419,902
Avg. Volume (20D)	594,039
Open	222.94
Previous Close	224.74
Day's Range	219.11 - 223.81
52-Week Range	200.98 - 248.24
Beta	0.88

About STE

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capit...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jun 1, 1992

Employees 18,000

Stock Exchange NYSE

Ticker Symbol STE

Website https://www.steris.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for STE stock is "Buy." The 12-month stock price forecast is $265, which is an increase of 18.92% from the latest price.

Stock Forecasts

Next Earnings Release

STERIS is scheduled to release its earnings on May 14, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+3.55%

STERIS shares are trading higher. The company anno... Unlock content with Pro Subscription

5 months ago

-5.28%

Steris shares are trading lower after the company reported worse-than-expected Q2 revenue results

News

2 weeks ago · zacks.com

Is it the Right Time to Hold STERIS Stock in Your Portfolio?

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

1 month ago · seekingalpha.com

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with manage...

1 month ago · zacks.com

Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

Steris (STE) International Revenue in Focus: Trends and Expectations

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

2 months ago · seekingalpha.com

STERIS plc (STE) Q3 2025 Earnings Call Transcript

STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Offic...

2 months ago · zacks.com

STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.

2 months ago · zacks.com

Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street...

2 months ago · zacks.com

Steris (STE) Matches Q3 Earnings Estimates

Steris (STE) came out with quarterly earnings of $2.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.22 per share a year ago.

2 months ago · reuters.com

Steris lowers annual profit forecast due to a stronger dollar

Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar.

2 months ago · zacks.com

Can Steris (STE) Keep the Earnings Surprise Streak Alive?

Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Load More News